Title: Genetically Engineered Salmon Labeling Act
Policy area: Health

Summary:
Genetically Engineered Salmon Labeling Act
This bill requires the market name of genetically engineered (commonly called "genetically modified" or "GMO") salmon to include "Genetically Engineered" or "GE" in front of the existing market name.
The Department of Health and Human Services must ensure that an independent scientific and technical advisory organization reports on: (1) the Food and Drug Administration (FDA) environmental assessment of AquAdvantage Salmon, and (2) each FDA environmental assessment in support of approval of a new animal drug application for a genetically engineered finfish intended for human consumption. Upon receipt of a report from the independent organization, the FDA must conduct a second environmental assessment of the fish, taking into account the report's findings. The approval of a new animal drug application for a genetically engineered fish does not take effect until the second environmental assessment of the fish is completed.

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[S. 1528 Introduced in Senate (IS)]

<DOC>






115th CONGRESS
  1st Session
                                S. 1528

 To amend the market name of genetically altered salmon in the United 
                    States, and for other purposes.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             July 11, 2017

    Ms. Murkowski (for herself, Mr. Sullivan, Ms. Cantwell, and Mr. 
   Merkley) introduced the following bill; which was read twice and 
  referred to the Committee on Health, Education, Labor, and Pensions

_______________________________________________________________________

                                 A BILL


 
 To amend the market name of genetically altered salmon in the United 
                    States, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Genetically Engineered Salmon 
Labeling Act''.

SEC. 2. PURPOSES.

    It is the purpose of this Act to--
            (1) ensure that consumers in the United States can make 
        informed decisions when purchasing salmon; and
            (2) authorize an independent scientific and technical 
        advisory organization to conduct a review of--
                    (A) the possible effects of genetically engineered 
                salmon on wild salmon stocks; and
                    (B) the Food and Drug Administration's approval of 
                genetically engineered salmon for human consumption.

SEC. 3. MARKET NAME FOR GENETICALLY ENGINEERED SALMON.

    (a) In General.--Notwithstanding any other provision of law, for 
purposes of applying the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 301 et seq.), the acceptable market name of any salmon that is 
genetically engineered shall include the words ``Genetically 
Engineered'' or ``GE'' prior to the existing acceptable market name.
    (b) Definition.--For purposes of this section, salmon is 
genetically engineered if it has been modified by recombinant DNA 
(rDNA) techniques, including the entire lineage of salmon that contain 
the rDNA modification.

SEC. 4. THIRD-PARTY REVIEW OF CERTAIN SALMON APPROVAL.

    (a) Independent Scientific Organization Review and Report.--The 
Secretary of Health and Human Services (referred to in this section as 
the ``Secretary'') shall ensure that the National Academy of Sciences, 
or a similar independent scientific and technical advisory 
organization, conducts a review of, and submits to the Secretary a 
report on--
            (1) the environmental assessment carried out by the Food 
        and Drug Administration and released on November 12, 2015, in 
        support of approval of the new animal drug application under 
        section 512 of the Federal Food, Drug, and Cosmetic Act (21 
        U.S.C. 360b) with respect to AquAdvantage Salmon, taking into 
        account the impact of AquAdvantage Salmon on wild stocks of 
        salmon and related wild ecosystems; and
            (2) each environmental assessment carried out by the Food 
        and Drug Administration in support of an approval of a new 
        animal drug application under section 512 of the Federal Food, 
        Drug, and Cosmetic Act (21 U.S.C. 360b) related to a 
        genetically engineered finfish intended for human consumption.
    (b) Second FDA Environmental Assessment.--After receipt of a report 
under paragraph (1) or (2) of subsection (a), the Secretary shall 
conduct a second environmental assessment with respect to approval of 
the application described in such paragraph (1) or (2), taking into 
account the findings in such report.
    (c) Effective Date of Approval.--Notwithstanding any other 
provision of law, the approval of a new animal drug application with 
respect to which review of an environmental assessment is required 
under subsection (a) shall not take effect until the Secretary 
completes a second environmental assessment under subsection (b).
                                 <all>